Join
Live feed
·
PRReleasevia Quantisnow
Candel Therapeutics Inc. logo

Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026

ByQuantisnow·Wall Street's wire, on your screen.
CADL· Candel Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CADL (Candel Therapeutics Inc.) and more on Quantisnow.